Clinical Trials
16 trialsNCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
NCT04113616 2024-03-22
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Kartos Therapeutics, Inc.
Phase 1/2 Terminated
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT02957032 2023-10-10
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Philogen S.p.A.
Phase 1 Terminated
NCT01158885 2021-10-26
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Terminated
NCT02298166 2021-10-06
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
Phase 3 Terminated
NCT00439296 2021-03-17
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT03135028 2020-03-06
Japanese AML
Gilead Sciences
Phase 1 Terminated
NCT00939653 2020-02-19
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Terminated
NCT02954653 2019-11-21
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
Phase 1 Terminated
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT00928200 2019-02-19
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01034410 2011-02-02
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
Antisoma Research
Phase 2 Terminated